Literature DB >> 17619827

Platelet GPIbalpha, GPIV and vWF polymorphisms and fatal pre-hospital MI among middle-aged men.

Minna Pellikka1, Lassi Narhi, Markus Perola, Antti Penttila, Pekka J Karhunen, Jussi Mikkelsson.   

Abstract

BACKGROUND: The binding of platelet glycoprotein (GP) Ib-IX-V receptor complex to subendothelial collagen via von Willebrand factor is the initial step of the formation of platelet thrombi following atherosclerotic plaque rupture. Platelet GPIV binds to collagen and/or thrombospondin and further activates platelets. Genetic variation in these proteins could associate with platelet aggregability and the risk of myocardial infarction (MI). METHODS AND
RESULTS: We studied the associations of polymorphisms of GPIbalpha, GPIV and von Willebrand factor with the extent of coronary atherosclerosis, coronary narrowing, and fatal MI in an autopsy series of 300 middle-aged, Caucasian Finnish men who had suffered sudden out-of-hospital death. 31% of men with MI under the age of 50 carried the GPIbalpha HPA-2 ThrThr/Kozak TT haplotype as opposed to 62% of control men (OR 0.27, 95% CI 0.08-0.93, P = 0.03). In addition, 7% of men with MI under the age of 50 carried the GPIV AA genotype versus 29% of control men (OR 0.16, 95% CI 0.03-0.98, P < 0.05). These associations were not due to any effects of these gene variants on the coronary atherosclerotic changes. The G/A polymorphism of the von Willebrand factor gene failed to show any association with MI or coronary atherosclerosis in this series of men.
CONCLUSIONS: The combined ThrThr/TT haplotype of GPIbalpha as well as the AA genotype of GPIV seem to decrease the risk of fatal MI among men during early middle-age.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17619827     DOI: 10.1007/s11239-007-0072-2

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  41 in total

1.  Kozak sequence polymorphism in the platelet GPIbalpha gene is not associated with risk of myocardial infarction.

Authors:  S A Croft; K K Hampton; M E Daly; R P Steeds; K S Channer; N J Samani
Journal:  Blood       Date:  2000-03-15       Impact factor: 22.113

Review 2.  CD36 and atherosclerosis.

Authors:  R L Silverstein; M Febbraio
Journal:  Curr Opin Lipidol       Date:  2000-10       Impact factor: 4.776

3.  Role of 4 platelet membrane glycoprotein polymorphisms on experimental arterial thrombus formation in men.

Authors:  Y Cadroy; K S Sakariassen; J P Charlet; C Thalamas; B Boneu; P Sie
Journal:  Blood       Date:  2001-11-15       Impact factor: 22.113

4.  Variability of the CD36 gene in West Africa.

Authors:  A Gelhaus; A Scheding; E Browne; G D Burchard; R D Horstmann
Journal:  Hum Mutat       Date:  2001-11       Impact factor: 4.878

5.  Oxidized LDL-induced NF-kappa B activation and subsequent expression of proinflammatory genes are defective in monocyte-derived macrophages from CD36-deficient patients.

Authors:  M Janabi; S Yamashita; K Hirano; N Sakai; H Hiraoka; K Matsumoto; Z Zhang; S Nozaki; Y Matsuzawa
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-08       Impact factor: 8.311

6.  Family history as a risk factor for primary cardiac arrest.

Authors:  Y Friedlander; D S Siscovick; S Weinmann; M A Austin; B M Psaty; R N Lemaitre; P Arbogast; T E Raghunathan; L A Cobb
Journal:  Circulation       Date:  1998-01-20       Impact factor: 29.690

7.  Kozak sequence polymorphism of the glycoprotein (GP) Ibalpha gene is a major determinant of the plasma membrane levels of the platelet GP Ib-IX-V complex.

Authors:  V Afshar-Kharghan; C Q Li; M Khoshnevis-Asl; J A López
Journal:  Blood       Date:  1999-07-01       Impact factor: 22.113

8.  Factors influencing the presence or absence of acute coronary artery thrombi in sudden ischaemic death.

Authors:  M J Davies; J M Bland; J R Hangartner; A Angelini; A C Thomas
Journal:  Eur Heart J       Date:  1989-03       Impact factor: 29.983

9.  von Willebrand factor but not alpha-thrombin binding to platelet glycoprotein Ibalpha is influenced by the HPA-2 polymorphism.

Authors:  Hans Ulrichts; Karen Vanhoorelbeke; Sandra Cauwenberghs; Stephan Vauterin; Hartmut Kroll; Sentot Santoso; Hans Deckmyn
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-05-29       Impact factor: 8.311

10.  Genetic susceptibility to death from coronary heart disease in a study of twins.

Authors:  M E Marenberg; N Risch; L F Berkman; B Floderus; U de Faire
Journal:  N Engl J Med       Date:  1994-04-14       Impact factor: 91.245

View more
  7 in total

1.  CD36 participates in a signaling pathway that regulates ROS formation in murine VSMCs.

Authors:  Wei Li; Maria Febbraio; Sekhar P Reddy; Dae-Yeul Yu; Masayuki Yamamoto; Roy L Silverstein
Journal:  J Clin Invest       Date:  2010-10-11       Impact factor: 14.808

2.  The association of platelet GPIb alpha 145 Thr/Met (HPA-2a/2b) with myocardial infarction and coronary artery disease.

Authors:  Marlena Culjak Aleksic; Jasna Mesaric
Journal:  J Thromb Thrombolysis       Date:  2010-04       Impact factor: 2.300

3.  Platelet CD36 surface expression levels affect functional responses to oxidized LDL and are associated with inheritance of specific genetic polymorphisms.

Authors:  Arunima Ghosh; Gurunathan Murugesan; Kan Chen; Li Zhang; Qing Wang; Maria Febbraio; Rita Marie Anselmo; Kandice Marchant; John Barnard; Roy L Silverstein
Journal:  Blood       Date:  2011-04-08       Impact factor: 22.113

4.  Systems analysis of gene ontology and biological pathways involved in post-myocardial infarction responses.

Authors:  Nguyen T Nguyen; Merry L Lindsey; Yu-Fang Jin
Journal:  BMC Genomics       Date:  2015-06-11       Impact factor: 3.969

5.  Common CD36 SNPs reduce protein expression and may contribute to a protective atherogenic profile.

Authors:  Latisha Love-Gregory; Richard Sherva; Timothy Schappe; Jian-Shen Qi; Jennifer McCrea; Samuel Klein; Margery A Connelly; Nada A Abumrad
Journal:  Hum Mol Genet       Date:  2010-10-08       Impact factor: 6.150

6.  Platelet glycoproteins and fibrinogen in recovery from idiopathic sudden hearing loss.

Authors:  Daniel Weiss; Bruno Neuner; Kerstin Gorzelniak; Alexis Bremer; Claudia Rudack; Michael Walter
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

7.  Glycoprotein Ibα Kozak polymorphism in patients presenting with early-onset acute coronary syndrome.

Authors:  Ebru Golcuk; Kivanc Yalin; Cansu Selcan Akdeniz; Erhan Teker; Başak Teker; Veysel Sabri Hancer; Ibrahim Altun; Murat Sezer; Reyhan Diz Kucukkaya; Aytac Oncul
Journal:  Arch Med Sci       Date:  2016-10-26       Impact factor: 3.318

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.